Table 3. Frequency and malignancy rates of the Bethesda categories by cyto-histological correlation from Thai series compared to other studies.
| FNA Bethesda category | Proportion (%) | |||||
|---|---|---|---|---|---|---|
| Average all Thai series [2011–2019] (9-12) | Bongiovanni et al. [2012] (14) | Sheffield et al. [2014] (13) | Krauss et al. [2016] (15) | Vuong et al. [2019] (16) | Ali and Cibas [2018] (1) | |
| Non-diagnostic | ||||||
| Frequency | 30.5 (16.3-47.6) | 12.9 | 13.0 | NA | 12.2 | NA |
| Risk of malignancy | 21.5 (14.3–28.4) | 16.8 | 18.7 | 12.0 | 2.0–19.1 | 5–10 |
| Benign | ||||||
| Frequency | 51.8 (34.7–68.1) | 59.3 | 59.8 | NA | 62.3 | NA |
| Risk of malignancy | 9.6 (2.8–19) | 3.7 | 6.5 | 5.0 | 0.7–8 | 0-3 |
| AUS/FLUS | ||||||
| Frequency | 4.9 (1.5–10.0) | 9.6 | 6.6 | NA | 8.0 | NA |
| Risk of malignancy | 38.4 (9–57.1) | 15.9 | 28.3 | 17.0 | 9.2–30.5 | 10–30 |
| FN/SFN | ||||||
| Frequency | 6.8 (2.4–21.7) | 10.1 | 11.0 | NA | 6.1 | NA |
| Risk of malignancy | 35.7 (6.1–63) | 26.1 | 33.1 | 25.0 | 28.9 | 25–40 |
| Suspicious for malignancy | ||||||
| Frequency | 3.1 (1.4–5.0) | 2.7 | 3.7 | NA | 3.7 | NA |
| Risk of malignancy | 77.7 (57–92.9) | 75.2 | 65.0 | 72.0 | 79.6 | 50–75 |
| Malignancy | ||||||
| Frequency | 9.1 (3.2–22.9) | 5.4 | 6.0 | NA | 7.4 | NA |
| Risk of malignancy | 95.2 (90–100) | 98.6 | 98.6 | 98.0 | 99.1 | 97–99 |
NA, not available.